Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005737 | cytoplasm | 2 | 12 |
GO:0031499 | TRAMP complex | 3 | 12 |
GO:0032991 | protein-containing complex | 1 | 12 |
GO:0110165 | cellular anatomical entity | 1 | 12 |
GO:0140513 | nuclear protein-containing complex | 2 | 12 |
GO:0005730 | nucleolus | 5 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043228 | non-membrane-bounded organelle | 3 | 1 |
GO:0043229 | intracellular organelle | 3 | 1 |
GO:0043232 | intracellular non-membrane-bounded organelle | 4 | 1 |
Related structures:
AlphaFold database: E9AY31
Term | Name | Level | Count |
---|---|---|---|
GO:0006139 | nucleobase-containing compound metabolic process | 3 | 12 |
GO:0006396 | RNA processing | 6 | 12 |
GO:0006725 | cellular aromatic compound metabolic process | 3 | 12 |
GO:0006807 | nitrogen compound metabolic process | 2 | 12 |
GO:0008152 | metabolic process | 1 | 12 |
GO:0009987 | cellular process | 1 | 12 |
GO:0016070 | RNA metabolic process | 5 | 12 |
GO:0031123 | RNA 3'-end processing | 7 | 12 |
GO:0034641 | cellular nitrogen compound metabolic process | 3 | 12 |
GO:0043170 | macromolecule metabolic process | 3 | 12 |
GO:0043631 | RNA polyadenylation | 6 | 12 |
GO:0044237 | cellular metabolic process | 2 | 12 |
GO:0044238 | primary metabolic process | 2 | 12 |
GO:0046483 | heterocycle metabolic process | 3 | 12 |
GO:0071076 | RNA 3' uridylation | 8 | 12 |
GO:0071704 | organic substance metabolic process | 2 | 12 |
GO:0090304 | nucleic acid metabolic process | 4 | 12 |
GO:1901360 | organic cyclic compound metabolic process | 3 | 12 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 12 |
GO:0004652 | obsolete polynucleotide adenylyltransferase activity | 6 | 12 |
GO:0005488 | binding | 1 | 8 |
GO:0016740 | transferase activity | 2 | 12 |
GO:0016772 | transferase activity, transferring phosphorus-containing groups | 3 | 12 |
GO:0016779 | nucleotidyltransferase activity | 4 | 12 |
GO:0043167 | ion binding | 2 | 8 |
GO:0043169 | cation binding | 3 | 8 |
GO:0046872 | metal ion binding | 4 | 8 |
GO:0050265 | RNA uridylyltransferase activity | 4 | 12 |
GO:0070566 | adenylyltransferase activity | 5 | 12 |
GO:0070569 | uridylyltransferase activity | 5 | 12 |
GO:0140098 | catalytic activity, acting on RNA | 3 | 12 |
GO:0140640 | catalytic activity, acting on a nucleic acid | 2 | 12 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 60 | 64 | PF00656 | 0.612 |
CLV_MEL_PAP_1 | 334 | 340 | PF00089 | 0.563 |
CLV_NRD_NRD_1 | 235 | 237 | PF00675 | 0.515 |
CLV_NRD_NRD_1 | 364 | 366 | PF00675 | 0.439 |
CLV_NRD_NRD_1 | 446 | 448 | PF00675 | 0.523 |
CLV_NRD_NRD_1 | 454 | 456 | PF00675 | 0.493 |
CLV_NRD_NRD_1 | 55 | 57 | PF00675 | 0.724 |
CLV_NRD_NRD_1 | 76 | 78 | PF00675 | 0.713 |
CLV_PCSK_FUR_1 | 53 | 57 | PF00082 | 0.781 |
CLV_PCSK_KEX2_1 | 364 | 366 | PF00082 | 0.362 |
CLV_PCSK_KEX2_1 | 454 | 456 | PF00082 | 0.497 |
CLV_PCSK_KEX2_1 | 53 | 55 | PF00082 | 0.699 |
CLV_PCSK_KEX2_1 | 76 | 78 | PF00082 | 0.659 |
CLV_PCSK_PC7_1 | 450 | 456 | PF00082 | 0.533 |
CLV_PCSK_SKI1_1 | 119 | 123 | PF00082 | 0.553 |
CLV_PCSK_SKI1_1 | 218 | 222 | PF00082 | 0.540 |
CLV_PCSK_SKI1_1 | 398 | 402 | PF00082 | 0.492 |
CLV_PCSK_SKI1_1 | 79 | 83 | PF00082 | 0.491 |
DOC_CYCLIN_yCln2_LP_2 | 111 | 114 | PF00134 | 0.693 |
DOC_MAPK_gen_1 | 258 | 266 | PF00069 | 0.438 |
DOC_MAPK_gen_1 | 364 | 370 | PF00069 | 0.438 |
DOC_MAPK_gen_1 | 454 | 462 | PF00069 | 0.301 |
DOC_MAPK_MEF2A_6 | 158 | 165 | PF00069 | 0.500 |
DOC_MAPK_MEF2A_6 | 260 | 268 | PF00069 | 0.448 |
DOC_PP2B_LxvP_1 | 111 | 114 | PF13499 | 0.693 |
DOC_PP2B_LxvP_1 | 173 | 176 | PF13499 | 0.394 |
DOC_PP4_FxxP_1 | 285 | 288 | PF00568 | 0.351 |
DOC_PP4_FxxP_1 | 376 | 379 | PF00568 | 0.449 |
DOC_PP4_FxxP_1 | 6 | 9 | PF00568 | 0.594 |
DOC_USP7_MATH_1 | 211 | 215 | PF00917 | 0.587 |
DOC_USP7_MATH_1 | 81 | 85 | PF00917 | 0.776 |
DOC_USP7_MATH_1 | 88 | 92 | PF00917 | 0.712 |
DOC_USP7_UBL2_3 | 374 | 378 | PF12436 | 0.432 |
DOC_WW_Pin1_4 | 133 | 138 | PF00397 | 0.426 |
DOC_WW_Pin1_4 | 424 | 429 | PF00397 | 0.571 |
DOC_WW_Pin1_4 | 91 | 96 | PF00397 | 0.685 |
LIG_14-3-3_CanoR_1 | 153 | 157 | PF00244 | 0.473 |
LIG_14-3-3_CanoR_1 | 21 | 27 | PF00244 | 0.617 |
LIG_14-3-3_CanoR_1 | 234 | 244 | PF00244 | 0.431 |
LIG_14-3-3_CanoR_1 | 413 | 419 | PF00244 | 0.484 |
LIG_14-3-3_CanoR_1 | 76 | 86 | PF00244 | 0.783 |
LIG_BRCT_BRCA1_1 | 237 | 241 | PF00533 | 0.443 |
LIG_BRCT_BRCA1_1 | 414 | 418 | PF00533 | 0.511 |
LIG_BRCT_BRCA1_1 | 93 | 97 | PF00533 | 0.682 |
LIG_EH1_1 | 319 | 327 | PF00400 | 0.358 |
LIG_FHA_1 | 103 | 109 | PF00498 | 0.625 |
LIG_FHA_1 | 169 | 175 | PF00498 | 0.434 |
LIG_FHA_1 | 210 | 216 | PF00498 | 0.495 |
LIG_FHA_1 | 403 | 409 | PF00498 | 0.432 |
LIG_FHA_1 | 80 | 86 | PF00498 | 0.752 |
LIG_FHA_2 | 136 | 142 | PF00498 | 0.460 |
LIG_FHA_2 | 157 | 163 | PF00498 | 0.352 |
LIG_FHA_2 | 357 | 363 | PF00498 | 0.375 |
LIG_LIR_Apic_2 | 283 | 288 | PF02991 | 0.271 |
LIG_LIR_Apic_2 | 375 | 379 | PF02991 | 0.475 |
LIG_LIR_Gen_1 | 238 | 248 | PF02991 | 0.444 |
LIG_LIR_Gen_1 | 31 | 42 | PF02991 | 0.497 |
LIG_LIR_Nem_3 | 238 | 244 | PF02991 | 0.402 |
LIG_LIR_Nem_3 | 31 | 37 | PF02991 | 0.493 |
LIG_LIR_Nem_3 | 360 | 366 | PF02991 | 0.439 |
LIG_LIR_Nem_3 | 415 | 421 | PF02991 | 0.422 |
LIG_NRBOX | 127 | 133 | PF00104 | 0.481 |
LIG_PCNA_yPIPBox_3 | 337 | 350 | PF02747 | 0.459 |
LIG_SH2_CRK | 166 | 170 | PF00017 | 0.451 |
LIG_SH2_CRK | 34 | 38 | PF00017 | 0.497 |
LIG_SH2_STAT3 | 329 | 332 | PF00017 | 0.426 |
LIG_SH2_STAT5 | 133 | 136 | PF00017 | 0.507 |
LIG_SH2_STAT5 | 280 | 283 | PF00017 | 0.490 |
LIG_SH2_STAT5 | 329 | 332 | PF00017 | 0.477 |
LIG_SH2_STAT5 | 385 | 388 | PF00017 | 0.300 |
LIG_SH2_STAT5 | 438 | 441 | PF00017 | 0.545 |
LIG_SH2_STAT5 | 474 | 477 | PF00017 | 0.424 |
LIG_SH3_3 | 386 | 392 | PF00018 | 0.418 |
LIG_SH3_3 | 93 | 99 | PF00018 | 0.547 |
LIG_SUMO_SIM_anti_2 | 323 | 328 | PF11976 | 0.368 |
LIG_SUMO_SIM_par_1 | 203 | 209 | PF11976 | 0.472 |
LIG_TRFH_1 | 133 | 137 | PF08558 | 0.500 |
LIG_UBA3_1 | 296 | 301 | PF00899 | 0.357 |
MOD_CK1_1 | 136 | 142 | PF00069 | 0.454 |
MOD_CK1_1 | 168 | 174 | PF00069 | 0.351 |
MOD_CK1_1 | 194 | 200 | PF00069 | 0.523 |
MOD_CK1_1 | 209 | 215 | PF00069 | 0.502 |
MOD_CK1_1 | 216 | 222 | PF00069 | 0.473 |
MOD_CK1_1 | 223 | 229 | PF00069 | 0.325 |
MOD_CK1_1 | 35 | 41 | PF00069 | 0.759 |
MOD_CK1_1 | 427 | 433 | PF00069 | 0.507 |
MOD_CK1_1 | 57 | 63 | PF00069 | 0.762 |
MOD_CK1_1 | 91 | 97 | PF00069 | 0.628 |
MOD_GlcNHglycan | 186 | 189 | PF01048 | 0.520 |
MOD_GlcNHglycan | 193 | 196 | PF01048 | 0.465 |
MOD_GlcNHglycan | 208 | 211 | PF01048 | 0.580 |
MOD_GlcNHglycan | 271 | 275 | PF01048 | 0.461 |
MOD_GlcNHglycan | 338 | 341 | PF01048 | 0.540 |
MOD_GlcNHglycan | 414 | 417 | PF01048 | 0.525 |
MOD_GlcNHglycan | 443 | 446 | PF01048 | 0.310 |
MOD_GlcNHglycan | 59 | 63 | PF01048 | 0.748 |
MOD_GlcNHglycan | 72 | 75 | PF01048 | 0.706 |
MOD_GlcNHglycan | 90 | 93 | PF01048 | 0.724 |
MOD_GSK3_1 | 152 | 159 | PF00069 | 0.463 |
MOD_GSK3_1 | 194 | 201 | PF00069 | 0.489 |
MOD_GSK3_1 | 209 | 216 | PF00069 | 0.449 |
MOD_GSK3_1 | 266 | 273 | PF00069 | 0.476 |
MOD_GSK3_1 | 28 | 35 | PF00069 | 0.684 |
MOD_GSK3_1 | 316 | 323 | PF00069 | 0.363 |
MOD_GSK3_1 | 398 | 405 | PF00069 | 0.410 |
MOD_GSK3_1 | 54 | 61 | PF00069 | 0.774 |
MOD_GSK3_1 | 77 | 84 | PF00069 | 0.731 |
MOD_GSK3_1 | 91 | 98 | PF00069 | 0.544 |
MOD_N-GLC_1 | 198 | 203 | PF02516 | 0.431 |
MOD_N-GLC_1 | 424 | 429 | PF02516 | 0.550 |
MOD_N-GLC_2 | 305 | 307 | PF02516 | 0.490 |
MOD_NEK2_1 | 156 | 161 | PF00069 | 0.269 |
MOD_NEK2_1 | 220 | 225 | PF00069 | 0.402 |
MOD_NEK2_1 | 235 | 240 | PF00069 | 0.453 |
MOD_NEK2_1 | 270 | 275 | PF00069 | 0.432 |
MOD_NEK2_1 | 342 | 347 | PF00069 | 0.468 |
MOD_NEK2_1 | 402 | 407 | PF00069 | 0.392 |
MOD_PIKK_1 | 213 | 219 | PF00454 | 0.390 |
MOD_PIKK_1 | 235 | 241 | PF00454 | 0.532 |
MOD_PIKK_1 | 430 | 436 | PF00454 | 0.517 |
MOD_PKA_1 | 54 | 60 | PF00069 | 0.798 |
MOD_PKA_2 | 152 | 158 | PF00069 | 0.514 |
MOD_PKA_2 | 235 | 241 | PF00069 | 0.428 |
MOD_PKA_2 | 336 | 342 | PF00069 | 0.508 |
MOD_PKA_2 | 412 | 418 | PF00069 | 0.486 |
MOD_PKA_2 | 54 | 60 | PF00069 | 0.798 |
MOD_PKB_1 | 77 | 85 | PF00069 | 0.706 |
MOD_Plk_1 | 266 | 272 | PF00069 | 0.379 |
MOD_Plk_4 | 107 | 113 | PF00069 | 0.646 |
MOD_Plk_4 | 398 | 404 | PF00069 | 0.390 |
MOD_Plk_4 | 414 | 420 | PF00069 | 0.368 |
MOD_Plk_4 | 81 | 87 | PF00069 | 0.760 |
MOD_ProDKin_1 | 133 | 139 | PF00069 | 0.436 |
MOD_ProDKin_1 | 424 | 430 | PF00069 | 0.566 |
MOD_ProDKin_1 | 91 | 97 | PF00069 | 0.688 |
MOD_SUMO_rev_2 | 262 | 266 | PF00179 | 0.543 |
TRG_DiLeu_BaLyEn_6 | 292 | 297 | PF01217 | 0.429 |
TRG_ENDOCYTIC_2 | 166 | 169 | PF00928 | 0.454 |
TRG_ENDOCYTIC_2 | 34 | 37 | PF00928 | 0.499 |
TRG_ER_diArg_1 | 334 | 337 | PF00400 | 0.561 |
TRG_ER_diArg_1 | 363 | 365 | PF00400 | 0.398 |
TRG_ER_diArg_1 | 53 | 56 | PF00400 | 0.750 |
TRG_ER_diArg_1 | 76 | 79 | PF00400 | 0.711 |
TRG_NES_CRM1_1 | 164 | 179 | PF08389 | 0.484 |
TRG_Pf-PMV_PEXEL_1 | 147 | 151 | PF00026 | 0.530 |
TRG_Pf-PMV_PEXEL_1 | 364 | 369 | PF00026 | 0.475 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1PD64 | Leptomonas seymouri | 62% | 85% |
A0A0S4IQ72 | Bodo saltans | 28% | 87% |
A0A1X0NU61 | Trypanosomatidae | 36% | 100% |
A0A3Q8IDQ5 | Leishmania donovani | 88% | 80% |
A0A3S5IS02 | Trypanosoma rangeli | 38% | 100% |
A4HEQ5 | Leishmania braziliensis | 71% | 100% |
A4I1Y4 | Leishmania infantum | 88% | 80% |
C9ZS34 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 35% | 98% |
Q4Q9E2 | Leishmania major | 87% | 100% |
V5B9F7 | Trypanosoma cruzi | 37% | 100% |